Express Scripts (ESRX)
ESRX (NASDAQ:Health Services)
$62.68
-0.20
-0.32%
Today's Range: 62.00 - 63.20 |
ESRX Avg Daily Volume: 5,400,000
| Last Update: 05/24/13 - 4:00 PM EDT |
| Volume: 4,836,741 |
| YTD Performance: 15.72%
|
| Open: $62.34 |
| Previous Close: $62.88 |
| 52 Week Range: $49.79 -
$66.06 |
| Oustanding Shares: 817,529,000 |
| Market Cap: 51,087,387,210 |
6-Month Chart
TheStreet Ratings Grade for ESRX
| Buy |
Hold
|
Sell
|
| A+ |
A |
A- |
B+ |
B |
B- |
C+ |
C |
C- |
D+ |
D |
D- |
E+ |
E |
E- |
F |
Analysts Ratings
| Historical Rec |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
| Strong Buy |
10 |
9 |
11 |
11 |
| Moderate Buy |
3 |
3 |
3 |
3 |
| Hold |
2 |
3 |
4 |
4 |
| Moderate Sell |
0 |
0 |
0 |
0 |
| Strong Sell |
0 |
0 |
0 |
0 |
| Mean Rec. |
1.43 |
1.57 |
1.58 |
1.58 |
| Latest Dividend: |
0.00 |
| Latest Dividend Yield: |
0.00% |
| Dividend Ex-Date: |
06/27/05 |
| Price Earnings Ratio: |
36.98 |
|
| Price Earnings Comparisons: |
| ESRX |
Sector Avg. |
S&P 500 |
| 36.98 |
35.70 |
17.70 |
| Price Performance History (%Change): |
| 3 Mo |
1 Yr |
3 Y |
|
12.33%
|
20.41%
|
24.25%
|
|
| GROWTH |
12 Mo |
3 Yr |
CAGR |
| Revenue |
103.50 |
2.79 |
0.55 |
| Net Income |
4.30 |
0.64 |
0.18 |
| EPS |
-30.80 |
0.15 |
0.05 |
| Earnings for ESRX: |
| EBITDA |
4.66B |
| Revenue |
93.86B |
|
Average Earnings Estimates
;Qtr (09/13);FY (12/13);FY (12/14)&HEADING_LIST1=Qtr (06/12);Qtr (09/12);FY (12/12);FY (12/13)) |
|
| Average Estimate |
$1.10 |
$1.09 |
$4.30 |
$4.93 |
| Number of Analysts |
11 |
10 |
12 |
13 |
| High Estimate |
$1.13 |
$1.11 |
$4.32 |
$5.15 |
| Low Estimate |
$1.09 |
$1.07 |
$4.28 |
$4.75 |
| Prior Year |
$0.88 |
$1.02 |
$3.74 |
$4.30 |
| Growth Rate (Year over Year) |
25.31% |
6.57% |
14.91% |
14.81% |
| Jul 17, 2012 | 7:30 AM EDT
One has had a sharp surge, and the other is recovering from a hard hit.
Jul 11, 2012 | 5:30 AM EDT
Stephanie Link, director of research at TheStreet, likes CVS for more than the market share they are gaining from Walgreen.
| Jun 10, 2012 | 10:30 AM EDT
At these multiples, and with such strong fundamentals, you’d be snagging a true bargain.
Jun 04, 2012 | 8:10 AM EDT
ESRX estimates were cut through 2013, BMO Capital said. Company is facing higher debt costs, following the Medco merger. Market Perform...
| May 15, 2012 | 10:30 AM EDT
These two beaten-down health care plays have low valuations but provide good long-term value and decent dividends.
| May 11, 2012 | 10:57 AM EDT
I get the sense Dimon didn't have a good grasp of these losses and was blindsided.
May 11, 2012 | 7:35 AM EDT
EXRS estimates lowered through 2013, Citigroup said. Strong results, but tweak EPS for taxes and shares. Buy rating and $66...
| May 10, 2012 | 3:24 PM EDT
With all three of these names set to report after the bell, I'm laying down some trades.
| May 10, 2012 | 1:06 PM EDT
Walgreen and Express Scripts have demographics on their side, and their fundamentals are sound.
| May 09, 2012 | 1:00 PM EDT
These lesser-known names could make some moves after they report later this week.
